Pacitti said the SNS portfolio delivered “strong above market” performance in 2025, growing over 8% organically year over year. He cited strength across long-term, short-term, and neonatal enteral feeding, including support from Avanos’s “Go Direct” transition in the U.K. that was executed in the third quarter of 2025.In the quarter, Avanos reported $0.29 in adjusted diluted EPS and $28 million of adjusted EBITDA. Adjusted gross margin was 53.4% and adjusted SG&A was 39.1% of revenue. For the full year, adj ...

Avanos Medical (NYSE:AVNS) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDave Pacitti - CEOJason Pickett - VP of Corporate Finance, Tax, and TreasurerScott Galovan - SVP and CFOConference Call ParticipantsDanny Stauder - Director and Equity Research AnalystOperatorNote that this call is being recorded on February 24th, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.Jason PickettGood morning, ever ...